Gardien, M.

patient infarction study treatment fondaparinux heart trial death disease heparin group lancet therapy angioplasty event aspirin result artery mortality intervention syndrome alteplase lancet publishing group enoxaparin ischemia reperfusion unfractionated st-segment prevention percutaneou cardiology st-segment elevation circulation point investigator factor unfractionated heparin infusion thrombolytic risk factors per-protocol analysis /iiia glycoprotein elevation streptokinase analysis reduction cardiol heart disease figure fibrinolytic therapy inhibitor effect safety ficacy ef ficacy end point randomised marker simoon dose response gusto european society tenecteplase procedure dosage 2.5 phase thrombolysi 2.5 mg fondaparinux angina dose -finding study reperfusion therapy tandem heart pvad per-protocol fibrinolytic signi ficant differences revascularization reteplase randomized